This video highlights preclinical activity of a novel FGFR inhibitor that has been tested alone and in combination with antihormonal therapy in breast cancer cell lines.
Dominik Mumberg, PhD
Advertisement
Articles by Dominik Mumberg, PhD
Advertisement
Latest Updated Articles
FGFR Inhibitor Shows Preclinical Activity in Breast CancerPublished: April 5th 2017 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?
2
FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC
3
Lower EDIC May Improve Local Tumor Control in Lung Cancer
4
Trial Assessing Savolitinib/Osimertinib in NSCLC Completes Enrollment
5
